FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043131514> ?p ?o ?g. }

• W3043131514 abstract "Abstract Background Tumors are heterogeneous in nature, composed of different cell populations with various mutations and/or phenotypes. Using a single drug to encounter cancer progression is generally ineffective. To improve the treatment outcome, multiple drugs of distinctive mechanisms but complementary anticancer activities (combination therapy) are often used to enhance antitumor efficacy and minimize the risk of acquiring drug resistance. We report here the synergistic effects of salinomycin (a polyether antibiotic) and dasatinib (a Src kinase inhibitor). Methods Functionally, both drugs induce cell cycle arrest, intracellular reactive oxygen species (iROS) production, and apoptosis. We rationalized that an overlapping of the drug activities should offer an enhanced anticancer effect, either through vertical inhibition of the Src-STAT3 axis or horizontal suppression of multiple pathways. We determined the toxicity induced by the drug combination and studied the kinetics of iROS production by fluorescence imaging and flow cytometry. Using genomic and proteomic techniques, including RNA-sequencing (RNA-seq), reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and Western Blot, we subsequently identified the responsible pathways that contributed to the synergistic effects of the drug combination. Results Compared to either drug alone, the drug combination showed enhanced potency against MDA-MB-468, MDA-MB-231, and MCF-7 human breast cancer (BC) cell lines and tumor spheroids. The drug combination induces both iROS generation and apoptosis in a time-dependent manner, following a 2-step kinetic profile. RNA-seq data revealed that the drug combination exhibited synergism through horizontal suppression of multiple pathways, possibly through a promotion of cell cycle arrest at the G1/S phase via the estrogen-mediated S-phase entry pathway, and partially via the BRCA1 and DNA damage response pathway. Conclusion Transcriptomic analyses revealed for the first time, that the estrogen-mediated S-phase entry pathway partially contributed to the synergistic effect of the drug combination. More importantly, our studies led to the discoveries of new potential therapeutic targets, such as E2F2, as well as a novel drug-induced targeting of estrogen receptor β (ESR2) approach for triple-negative breast cancer treatment, currently lacking of targeted therapies." @default.
• W3043131514 created "2020-07-23" @default.
• W3043131514 creator A5025568667 @default.
• W3043131514 creator A5057160588 @default.
• W3043131514 creator A5064914431 @default.
• W3043131514 creator A5076793053 @default.
• W3043131514 date "2020-07-16" @default.
• W3043131514 modified "2023-10-15" @default.
• W3043131514 title "Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor β" @default.
• W3043131514 cites W1567719786 @default.
• W3043131514 cites W1968005886 @default.
• W3043131514 cites W1982224118 @default.
• W3043131514 cites W1983933325 @default.
• W3043131514 cites W1984252723 @default.
• W3043131514 cites W1988324747 @default.
• W3043131514 cites W1988698939 @default.
• W3043131514 cites W2001198210 @default.
• W3043131514 cites W2017714068 @default.
• W3043131514 cites W2026742412 @default.
• W3043131514 cites W2035903949 @default.
• W3043131514 cites W2037588005 @default.
• W3043131514 cites W2039109621 @default.
• W3043131514 cites W2039648383 @default.
• W3043131514 cites W2041929955 @default.
• W3043131514 cites W2047920084 @default.
• W3043131514 cites W2049682885 @default.
• W3043131514 cites W2053363358 @default.
• W3043131514 cites W2055845643 @default.
• W3043131514 cites W2064768825 @default.
• W3043131514 cites W2066003961 @default.
• W3043131514 cites W2083426370 @default.
• W3043131514 cites W2086064725 @default.
• W3043131514 cites W2088279063 @default.
• W3043131514 cites W2088305282 @default.
• W3043131514 cites W2096745115 @default.
• W3043131514 cites W2101599998 @default.
• W3043131514 cites W2103562758 @default.
• W3043131514 cites W2104296738 @default.
• W3043131514 cites W2104519300 @default.
• W3043131514 cites W2105017561 @default.
• W3043131514 cites W2114229735 @default.
• W3043131514 cites W2120656656 @default.
• W3043131514 cites W2128321558 @default.
• W3043131514 cites W2140199760 @default.
• W3043131514 cites W2154243294 @default.
• W3043131514 cites W2154534312 @default.
• W3043131514 cites W2155490728 @default.
• W3043131514 cites W2166820820 @default.
• W3043131514 cites W2169456326 @default.
• W3043131514 cites W2170366015 @default.
• W3043131514 cites W2174425170 @default.
• W3043131514 cites W2179438025 @default.
• W3043131514 cites W2186340798 @default.
• W3043131514 cites W2208054810 @default.
• W3043131514 cites W2267686699 @default.
• W3043131514 cites W2292820165 @default.
• W3043131514 cites W2443282782 @default.
• W3043131514 cites W2535520139 @default.
• W3043131514 cites W2547029001 @default.
• W3043131514 cites W2549615193 @default.
• W3043131514 cites W2557218664 @default.
• W3043131514 cites W2561569070 @default.
• W3043131514 cites W2567527235 @default.
• W3043131514 cites W2588629285 @default.
• W3043131514 cites W2607307935 @default.
• W3043131514 cites W2611050343 @default.
• W3043131514 cites W2611118251 @default.
• W3043131514 cites W2615322840 @default.
• W3043131514 cites W2617112080 @default.
• W3043131514 cites W2770557504 @default.
• W3043131514 cites W2796576424 @default.
• W3043131514 cites W2891477819 @default.
• W3043131514 cites W2891647167 @default.
• W3043131514 cites W2900334276 @default.
• W3043131514 cites W2903713666 @default.
• W3043131514 cites W2904098288 @default.
• W3043131514 cites W2911188335 @default.
• W3043131514 cites W2913712566 @default.
• W3043131514 cites W2938285217 @default.
• W3043131514 doi "https://doi.org/10.1186/s12885-020-07134-3" @default.
• W3043131514 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7364656" @default.
• W3043131514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32678032" @default.
• W3043131514 hasPublicationYear "2020" @default.
• W3043131514 type Work @default.
• W3043131514 sameAs 3043131514 @default.
• W3043131514 citedByCount "8" @default.
• W3043131514 countsByYear W30431315142020 @default.
• W3043131514 countsByYear W30431315142021 @default.
• W3043131514 countsByYear W30431315142022 @default.
• W3043131514 crossrefType "journal-article" @default.
• W3043131514 hasAuthorship W3043131514A5025568667 @default.
• W3043131514 hasAuthorship W3043131514A5057160588 @default.
• W3043131514 hasAuthorship W3043131514A5064914431 @default.
• W3043131514 hasAuthorship W3043131514A5076793053 @default.
• W3043131514 hasBestOaLocation W30431315141 @default.
• W3043131514 hasConcept C104317684 @default.
• W3043131514 hasConcept C150194340 @default.
• W3043131514 hasConcept C162317418 @default.
• W3043131514 hasConcept C190283241 @default.
• W3043131514 hasConcept C2777583451 @default.

• next